GSC
ITRM

Ground Swell Capital’s Iterum Therapeutics ITRM Stock Holding History

Ground Swell Capital’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,477
Closed -$6.86K – 146
2025
Q4 		$6.86K Buy
+20,477
New +$11K 0.01% 78

Other funds holding ITRM

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ground Swell Capital's ITRM Position: Q1 2026 in Review

Ground Swell Capital sold out of Iterum Therapeutics (ITRM) in Q1 2026, closing a stake of 20,477 shares — an estimated $6.86K sold.

Ground Swell Capital first reported a position in ITRM in Q4 2025 and held it in 1 quarter. The position peaked at $6.86K in Q4 2025. 18 funds tracked by Wall St. Rank hold ITRM as of Q1 2026.

  • Ground Swell Capital reported no remaining Iterum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ground Swell Capital sold 20,477 Iterum Therapeutics shares in Q1 2026, an estimated $6.86K.
  • Ground Swell Capital first reported a position in Iterum Therapeutics in Q4 2025 and held it in 1 quarter.
  • Ground Swell Capital's Iterum Therapeutics position peaked at $6.86K in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2026.

Based on Ground Swell Capital's 13F filing for Q1 2026, filed 21 Apr 2026.